A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
Latest Information Update: 22 Oct 2024
At a glance
- Drugs SSGJ-705 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 03 May 2024 New trial record